Citizens JMP analyst Jason Butler lowered the firm’s price target on Argenx (ARGX) to $699 from $701 and keeps an Outperform rating on the shares. Argenx recently reported Q1 results slightly ahead of consensus estimates, underscoring continued success for the VYVGART franchise, the analyst tells investors in a research note. The firm anticipates the pre-filled syringe launch will be a key demand driver in 2025 and beyond.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx upgraded to Outperform from Neutral at Baird
- Argenx Se: Buy Rating Affirmed Amid Pricing Strategy Confidence and Promising Growth Prospects
- Argenx price target lowered to EUR 525 from EUR 575 at Deutsche Bank
- Argenx Reports Record Growth and Strategic Success
- Argenx price target lowered to EUR 700 from EUR 740 at JPMorgan